Ref. | # | Median follow up (mo) | Stage | Prescription dose | Local control | Dose to the optic pathway | Vision impairment | Blindness |
---|---|---|---|---|---|---|---|---|
Madani [22]CTCAE v2 | 84 | 40 | T4: 29% | 70 Gy/35 frx | 77.4% | ON/OC constraint: V60 <5%. | Acute: 1.4% | None |
Actual Dose to 2% vol¶: | Late:1.4% Grade 3 visual impairment related to IMRT in non-previously treated pts; 2.7% grade 3 impairment due to tumor invasion in both non-previously irradiated & re-irradiated pts | |||||||
ON: | ||||||||
Ipsilateral 58.4 Gy; Contralateral 51.3 Gy | ||||||||
OC: 47.4 Gy | ||||||||
Combs [23] | 46 | 16 | T4: 65% | PTV 60 Gy/30 frx, bst CTV 66 Gy/33 frxǂ | 81% at 2 yrs | ON/OC constraint: 54 Gy. | None | None |
RON: 37.9 Gyǂ | ||||||||
LON: 37.4 Gyǂ | ||||||||
OC: 25.3 Gyǂ | ||||||||
Daly [24] | 36 | 51 | T4: 69% | GTV 70 Gy/33 frx, CTV 58 Gy/33 frxǂ | 63.9% | ON/OC constraints: D1% 54 Gy (ON), 45 Gy (OC). | N/a | None |
Actual Dmax: | ||||||||
OC: 52.3 Gy¶; | ||||||||
ON: | ||||||||
Ipsilateral 59.1 Gy¶ | ||||||||
Contralateral 45.2 Gy¶ | ||||||||
Hoppe [25]* | 37 | 28 | T4: 55% | PTV1 70 Gy | 72.9% | ON/OC constraint: < 54 Gy. | No RTOG grade 3–4 toxicity | None |
PTV2 60 Gy | Actual Dmax: | |||||||
PTV3 54 Gy | ON | |||||||
All in 33 frx | ipsilateral 53 Gyǂ | |||||||
contralateral 41 Gyǂ | ||||||||
OC 50 Gyǂ | ||||||||
Wiegner [26]CTCAE v3 | 52 | 26.6 | T4: 76% | High risk PTV 66 Gy/33 frx, 74.4 Gy, 1.2 Gy bid in 5 pts; SRS/SRT bst in 4 pts: 8 Gy x 1 frx or 5 Gy x 2 frx | 75% | ON/OC constraint: 45 Gy, 63 Gy if treated with bid schedule. | 1 grade 3 optic neuropathy related to herpes zoster infection, 1 grade 3 corneal ulcer | None |
Postoperative: 77% | ||||||||
 |  |  |  |  | Definitive: 60% |  |  |  |